Anti Infective Agents Impact in COVID-19 Pneumonia (AZITHROVID)

Centre d'Investigation Clinique et Technologique 805

Status: Completed

Conditions: COVID; Pneumonia, Viral

Treatments: Drug: favorable outcome

Study type: Observational

Funder types: Other

Identifiers

NCT04453501

AZITHROVID

INDS (Registry Identifier)

Details and patient eligibility

About

During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.

Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.

Enrollment: 132 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged over 18 years old
• hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry,
• admitted outside an intensive care unit, in a medicine ward

Exclusion criteria

• patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia

Trial design

132 participants in 1 patient group

Azithromycin or non-azithromycin group

Description:

Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.

Treatment:

Drug: favorable outcome